The analysis included epilepsy surgical outcomes between 1988 and 1998. Patient follow-up reviews ranged in one to 14 years, with the average length of six years. Outcomes will be presented April 27 at the American Academy of Neurology annual meeting in SAN FRANCISCO BAY AREA by Gregory Cascino, M.D., seat of the Mayo Clinic Division of Epilepsy, Division of Neurology. The surgery involves removing the epileptic human brain tissue, a procedure called a focal cortical resection. Partial epilepsy may be the most common seizure disorder, affecting over one million patients in the usa and comprising 90 % of adult epilepsy instances.The median overall survival in the intention-to-treat population was 12.three months in the iniparib group and 7.7 months in the chemotherapy-alone group . A complete of 30 of 59 patients in the chemotherapy-alone group crossed to receive iniparib in conjunction with gemcitabine and carboplatin, after disease progression occurred. Individuals who crossed over received a median of 1 1.5 cycles of iniparib; 25 of the 30 individuals discontinued treatment after one or two cycles. In 1 of the 30 patients , there was an unconfirmed partial response, and 4 of the 30 patients had steady disease. Safety Table 3Table 3Common Adverse Events in the Safety Inhabitants.